Friday, November 15 | San Francisco, CA

California Life Sciences AssociationCalifornia Life Sciences Association

Rising Star


Cortexyme is developing therapeutics based on data supporting a new theory of the cause of Alzheimer’s and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies. Their leading candidate, COR388, is currently being studied in a placebo controlled Phase 1b trial in patients with Alzheimer’s disease at two sites in the US. Initially working out of JLABS’ Bay Area facility, Cortexyme has now completed animal studies as well as a Phase I safety test to set the stage for a Phase II human study.

Cortexyme got started with some marquee backers, including Pfizer, Takeda Ventures, Lamond Family, Breakout Ventures, Dolby Family Venture, Sequoia Capital, Vulcan Capital, Verily Life Sciences, EPIQ Capital Group, RSL Investments, Huizenga Capital, and an unidentified long-term mutual fund.